Subjective cognitive decline (SCD) may result from many conditions, including Alzheimer’s disease (AD).
Objective:
In this study, we searched for a specific pattern of SCD in asymptomatic individuals at risk for AD.
Methods:
Cognitively normal older adults (N = 318) reporting SCD and their informants were enrolled in the INSIGHT-PreAD cohort. We examined the relationship between six SCD measures and both cognitive scores and AD neuroimaging markers (amyloid burden, hippocampal atrophy and brain hypometabolism). An awareness of cognitive decline index (ACDI) has been introduced based on the subject-informant discrepancy in a questionnaire of SCD and participants with low versus high awareness were compared.
Results:
Scores in the INSIGHT-PreAD SCD questionnaires did not correlate with AD neuroimaging markers. As well, no correlation has been found between SCD measures and cognitive scores. Comparing subjects with a low (n = 19) and high (n = 86) level of awareness, no significant difference in terms of demography, neuropsychiatric symptoms, autonomy, quality of life, cognition, and hippocampal volume was found. However, the “low awareness” group showed greater amyloid burden and lower cortical metabolism, compared to the “high awareness” group.
Conclusion:
This study provided additional evidence that reporting SCD by itself is not a specific symptom of preclinical AD. Conversely, a low cognitive awareness (namely, when subjects report fewer difficulties than their relatives do) may represent a very early form of anosognosia and serve as a specific indicator of preclinical AD. This finding is of key importance as an enrichment factor to consider in both clinical practice and research trials.
JessenF, AmariglioRE, van BoxtelM, BretelerM, CeccaldiM, ChetelatG, DuboisB, DufouilC, EllisKA, van der FlierWM, GlodzikL, van HartenAC, de LeonMJ, McHughP, MielkeMM, MolinuevoJL, MosconiL, OsorioRS, PerrotinA, PetersenRC, RabinLA, RamiL, ReisbergB, RentzDM, SachdevPS, de la SayetteV, SaykinAJ, ScheltensP, ShulmanMB, SlavinMJ, SperlingRA, StewartR, UspenskayaO, VellasB, VisserPJ, WagnerM, Subjective Cognitive Decline Initiative (SCD-I) Working, Group (2014) A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimers Dement10, 844–852.
2.
MitchellAJ, BeaumontH, FergusonD, YadegarfarM, StubbsB (2014) Risk of dementia and mild cognitive impairment in older people with subjective memory complaints: Meta-analysis. Acta Psychiatr Scand130, 439–451.
3.
ZlatarZZ, MooreRC, PalmerBW, ThompsonWK, JesteDV (2014) Cognitive complaints correlate with depression rather than concurrent objective cognitive impairment in the successful aging evaluation baseline sample. J Geriatr Psychiatry Neurol27, 181–187.
4.
MeremaMR, SpeelmanCP, FosterJK, KaczmarekEA (2013) Neuroticism (not depressive symptoms) predicts memory complaints in some community-dwelling older adults. Am J Geriatr Psychiatry21, 729–736.
5.
TardyM, GonthierR, BarthelemyJC, RocheF, Crawford-AchourE (2015) Subjective sleep and cognitive complaints in 65 year old subjects: A significant association. The PROOF cohort. J Nutr Health Aging19, 424–430.
6.
PondsRW, CommissarisKJ, JollesJ (1997) Prevalence and covariates of subjective forgetfulness in a normal population in The Netherlands. Int J Aging Hum Dev45, 207–221.
7.
PrinceM, BryceR, AlbaneseE, WimoA, RibeiroW, FerriCP (2013) The global prevalence of dementia: A systematic review and metaanalysis. Alzheimers Dement9, 63–75.e2.
8.
CacchionePZ, PowlishtaKK, GrantEA, BucklesVD, MorrisJC (2003) Accuracy of collateral source reports in very mild to mild dementia of the Alzheimer type. J Am Geriatr Soc51, 819–823.
9.
CarrDB, GrayS, BatyJ, MorrisJC (2000) The value of informant versus individual’s complaints of memory impairment in early dementia. Neurology55, 1724–1726.
10.
OrfeiMD, VarsiAE, BlundoC, CeliaE, CasiniAR, CaltagironeC, SpallettaG (2010) Anosognosia in mild cognitive impairment and mild Alzheimer’s disease: Frequency and neuropsychological correlates. Am J Geriatr Psychiatry18, 1133–1140.
11.
MichonA, DeweerB, PillonB, AgidY, DuboisB (1994) Relation of anosognosia to frontal lobe dysfunction in Alzheimer’s disease. J Neurol Neurosurg Psychiatry57, 805–809.
12.
DuboisB, HampelH, FeldmanHH, ScheltensP, AisenP, AndrieuS, BakardjianH, BenaliH, BertramL, BlennowK, BroichK, CavedoE, CrutchS, DartiguesJF, DuyckaertsC, EpelbaumS, FrisoniGB, GauthierS, GenthonR, GouwAA, HabertMO, HoltzmanDM, KivipeltoM, ListaS, MolinuevoJL, O’BryantSE, RabinoviciGD, RoweC, SallowayS, SchneiderLS, SperlingR, TeichmannM, CarrilloMC, CummingsJ, JackCRJr (2016) Proceedings of the Meeting of the International Working Group (IWG) and the American Alzheimer’s Association on “The Preclinical State of AD”, July 23 2, Washington DC U, Preclinical Alzheimer’s disease: Definition, natural history, and diagnostic criteria. Alzheimers Dement12, 292–323.
13.
AmievaH, CarcaillonL, Rouze L’Alzit-SchuermansP, MilletX, DartiguesJF, FabrigouleC (2007) Cued and uncued memory tests: Norms in elderly adults from the 3 Cities epidemiological study. Rev Neurol (Paris)163, 205–221.
14.
MonahanPO, AlderCA, KhanBA, StumpT, BoustaniMA (2014) The Healthy Aging Brain Care (HABC) Monitor: Validation of the Patient Self-Report Version of the clinical tool designed to measure and monitor cognitive, functional, and psychological health. Clin Interv Aging9, 2123–2132.
McNairD, KahnR (1983) Self-assessment of cognitive deficits. In Assessment in Geriatric Psychopharmacology, CrookT, FerrisA, BaltusR eds. Mark Powley Associates, New Canaan, CT, pp. 137–143.
17.
KauferDI, CummingsJL, KetchelP, SmithV, MacMillanA, ShelleyT, LopezOL, DeKoskyST (2000) Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci12, 233–239.
18.
SpielbergerC, GorsuchR, LusheneR, VaggP, JacobsG (1983) Manual for the state-trait anxiety inventory (form Y). Consulting Psychologists Press, Palo Alto.
19.
YesavageJA, BrinkTL, RoseTL, LumO, HuangV, AdeyM, LeirerVO (1982) Development and validation of a geriatric depressionscreening scale: A preliminary report. J Psychiatr Res17, 37–49.
20.
BucksRS, AshworthDL, WilcockGK, SiegfriedK (1996) Assessment of activities of daily living in dementia: Development of the Bristol Activities of Daily Living Scale. Age Ageing25, 113–120.
21.
BrooksR (1996) EuroQol: The current state of play. Health Policy37, 53–72.
22.
LimYY, SnyderPJ, PietrzakRH, UkiqiA, VillemagneVL, AmesD, SalvadoO, BourgeatP, MartinsRN, MastersCL, RoweCC, MaruffP (2015) Sensitivity of composite scores to amyloid burden in preclinical Alzheimer’s disease: Introducing the Z-scores of Attention, Verbal fluency, and Episodic memory for Nondemented older adults composite score. Alzheimers Dement (Amst)2, 19–26.
23.
DonohueMC, SperlingRA, SalmonDP, RentzDM, RamanR, ThomasRG, WeinerM, AisenPS, Australian Imaging, Biomarkers, and Lifestyle Flagship Study of Ageing, Alzheimer’s Disease Neuroimaging Initiative, Alzheimer’s Disease Cooperative Study (2014) The preclinical Alzheimer cognitive composite: Measuring amyloid-related decline. JAMA Neurol71, 961–970.
24.
LimYY, MaruffP, PietrzakRH, AmesD, EllisKA, HarringtonK, LautenschlagerNT, SzoekeC, MartinsRN, MastersCL, VillemagneVL, RoweCC, Research AIBL, Group (2014) Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer’s disease. Brain137, 221–231.
25.
ClarkCM, SchneiderJA, BedellBJ, BeachTG, BilkerWB, MintunMA, PontecorvoMJ, HeftiF, CarpenterAP, FlitterML, KrautkramerMJ, KungHF, ColemanRE, DoraiswamyPM, FleisherAS, SabbaghMN, SadowskyCH, ReimanEP, ZehntnerSP, SkovronskyDM, AV45-A07 Study, Group (2011) Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA305, 275–283.
26.
JackCRJr, KnopmanDS, JagustWJ, ShawLM, AisenPS, WeinerMW, PetersenRC, TrojanowskiJQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol9, 119–128.
27.
BessonFL, La JoieR, DoeuvreL, GaubertM, MezengeF, EgretS, LandeauB, BarreL, AbbasA, IbazizeneM, de La SayetteV, DesgrangesB, EustacheF, ChetelatG (2015) Cognitive and brain profiles associated with current neuroimaging biomarkers of preclinical Alzheimer’s disease. J Neurosci35, 10402–10411.
28.
JagustW, ReedB, MungasD, EllisW, DecarliC (2007) What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?Neurology69, 871–877.
29.
SperlingRA, AisenPS, BeckettLA, BennettDA, CraftS, FaganAM, IwatsuboT, JackCRJr, KayeJ, MontineTJ, ParkDC, ReimanEM, RoweCC, SiemersE, SternY, YaffeK, CarrilloMC, ThiesB, Morrison-BogoradM, WagsterMV, PhelpsCH (2011) Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 280–292.
30.
KimH, ChupinM, ColliotO, BernhardtBC, BernasconiN, BernasconiA (2012) Automatic hippocampal segmentation in temporal lobe epilepsy: Impact of developmental abnormalities. Neuroimage59, 3178–3186.
31.
RollsET, JoliotM, Tzourio-MazoyerN (2015) Implementation of anew parcellation of the orbitofrontal cortex in the automatedanatomical labeling atlas. Neuroimage122, 1–5.
32.
JackCRJr, LoweVJ, WeigandSD, WisteHJ, SenjemML, KnopmanDS, ShiungMM, GunterJL, BoeveBF, KempBJ, WeinerM, PetersenRC, Alzheimer’s Disease Neuroimaging, Initiative (2009) Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer’s disease: Implications for sequence of pathological events in Alzheimer’s disease. Brain132, 1355–1365.
33.
RabinLA, SmartCM, CranePK, AmariglioRE, BermanLM, BoadaM, BuckleyRF, ChetelatG, DuboisB, EllisKA, GiffordKA, JeffersonAL, JessenF, KatzMJ, LiptonRB, LuckT, MaruffP, MielkeMM, MolinuevoJL, NaeemF, PerrotinA, PetersenRC, RamiL, ReisbergB, RentzDM, Riedel-HellerSG, RisacherSL, RodriguezO, SachdevPS, SaykinAJ, SlavinMJ, SnitzBE, SperlingRA, TandetnikC, van der FlierWM, WagnerM, WolfsgruberS, SikkesSA (2015) Subjective cognitive decline in older adults: An overview of self-report measures used across 19 international research studies. J Alzheimers Dis48(Suppl 1), S63–S86.
34.
Glodzik-SobanskaL, ReisbergB, De SantiS, BabbJS, PirragliaE, RichKE, BrysM, de LeonMJ (2007) Subjective memory complaints: Presence, severity and future outcome in normal older subjects. Dement Geriatr Cogn Disord24, 177–184.
35.
DuboisB, FeldmanHH, JacovaC, CummingsJL, DekoskyST, Barberger-GateauP, DelacourteA, FrisoniG, FoxNC, GalaskoD, GauthierS, HampelH, JichaGA, MeguroK, O’BrienJ, PasquierF, RobertP, RossorM, SallowayS, SarazinM, de SouzaLC, SternY, VisserPJ, ScheltensP (2010) Revising the definition of Alzheimer’s disease: A new lexicon. Lancet Neurol9, 1118–1127.
36.
AizensteinHJ, NebesRD, SaxtonJA, PriceJC, MathisCA, TsopelasND, ZiolkoSK, JamesJA, SnitzBE, HouckPR, BiW, CohenAD, LoprestiBJ, DeKoskyST, HalliganEM, KlunkWE (2008) Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol65, 1509–1517.
37.
MintunMA, LarossaGN, ShelineYI, DenceCS, LeeSY, MachRH, KlunkWE, MathisCA, DeKoskyST, MorrisJC (2006) [11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease. Neurology67, 446–452.
38.
PikeKE, SavageG, VillemagneVL, NgS, MossSA, MaruffP, MathisCA, KlunkWE, MastersCL, RoweCC (2007) Beta-amyloid imaging and memory in non-demented individuals: Evidence for preclinical Alzheimer’s disease. Brain130, 2837–2844.
39.
VisserPJ, VerheyF, KnolDL, ScheltensP, WahlundLO, Freund-LeviY, TsolakiM, MinthonL, WallinAK, HampelH, BurgerK, PirttilaT, SoininenH, RikkertMO, VerbeekMM, SpiruL, BlennowK (2009) Prevalence and prognostic value of CSFmarkers of Alzheimer’s disease pathology in patients withsubjective cognitive impairment or mild cognitive impairment inthe DESCRIPA study: A prospective cohort study. LancetNeurol8, 619–627.
40.
StarksteinSE (2014) Anosognosia in Alzheimer’s disease: Diagnosis, frequency, mechanism and clinical correlates. Cortex61, 64–73.
